AR088816A1 - Proceso para preparar derivados de 1-acil-4-fenilsulfonilprolinamida y compuestos intermediarios - Google Patents
Proceso para preparar derivados de 1-acil-4-fenilsulfonilprolinamida y compuestos intermediariosInfo
- Publication number
- AR088816A1 AR088816A1 ARP120104226A ARP120104226A AR088816A1 AR 088816 A1 AR088816 A1 AR 088816A1 AR P120104226 A ARP120104226 A AR P120104226A AR P120104226 A ARP120104226 A AR P120104226A AR 088816 A1 AR088816 A1 AR 088816A1
- Authority
- AR
- Argentina
- Prior art keywords
- halogen
- formula
- alkyl
- phenyl
- defined above
- Prior art date
Links
- QSFXVWICUPNFBU-BYPYZUCNSA-N S(=O)(=O)=C1[C@H](NCC1)C(=O)N Chemical class S(=O)(=O)=C1[C@H](NCC1)C(=O)N QSFXVWICUPNFBU-BYPYZUCNSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 150000002367 halogens Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 150000003147 proline derivatives Chemical class 0.000 abstract 2
- 150000003568 thioethers Chemical class 0.000 abstract 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000001590 oxidative effect Effects 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 abstract 1
- -1 thio compound Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Proceso para la obtención de derivados de prolina de la fórmula (1) en la que: R¹ se elige entre alquilo C₁₋₇ y entre el resto de fórmula (6) en el que R⁴ se elige entre alquilo C₁₋₇, halógenoalquilo C₁₋₇ y entre fenilo, que está opcionalmente sustituido por halógeno; R² se elige entre halógeno y halógenoalquilo C₁₋₇; y R³ se elige entre hidrógeno, halógeno, halógenoalquilo C₁₋₇, alcoxi C₁₋₇, halógenoalcoxi C₁₋₇ y entre un anillo heterocíclico de 5 ó 6 eslabones que contiene uno o dos átomos de nitrógeno, dicho anillo está opcionalmente sustituido por alquilo C₁₋₇ o halógeno, que consta de los pasos siguientes: a) transformar un alcohol de la fórmula (2) en la que R¹ tiene el significado definido anteriormente, en el sulfonato de la fórmula (3) en la que R¹ tiene el significado definido anteriormente y R⁵ es alquilo C₁₋₇, halógenoalquilo C₁₋₇, o fenilo que está opcionalmente sustituido por alquilo C₁₋₇, nitro o bromo; b) hacer reaccionar el sulfonato de la fórmula (3) con un compuesto tio de la fórmula (4) en la que R² y R³ tienen los significados definidos anteriormente y R⁶ es hidrógeno o un grupo protector, para formar el tioéter de la fórmula (5) en la que R¹, R² y R³ tienen los significados definidos anteriormente; y c) oxidar el tioéter de la fórmula (5) para formar el derivado de prolina de la fórmula (1), en la que R¹, R² y R³ tienen los significados definidos anteriormente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11188728 | 2011-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088816A1 true AR088816A1 (es) | 2014-07-10 |
Family
ID=47143910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104226A AR088816A1 (es) | 2011-11-11 | 2012-11-09 | Proceso para preparar derivados de 1-acil-4-fenilsulfonilprolinamida y compuestos intermediarios |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8796471B2 (es) |
| EP (1) | EP2776392B1 (es) |
| JP (1) | JP5852254B2 (es) |
| KR (1) | KR101620769B1 (es) |
| CN (1) | CN103930400B (es) |
| AR (1) | AR088816A1 (es) |
| AU (1) | AU2012334123B2 (es) |
| BR (1) | BR112014011248B1 (es) |
| CA (1) | CA2853877C (es) |
| DK (1) | DK2776392T3 (es) |
| ES (1) | ES2582643T3 (es) |
| HU (1) | HUE029182T2 (es) |
| IL (1) | IL232424A (es) |
| MX (1) | MX339996B (es) |
| MY (1) | MY167569A (es) |
| PL (1) | PL2776392T3 (es) |
| RU (1) | RU2615997C2 (es) |
| SG (1) | SG11201402030VA (es) |
| SI (1) | SI2776392T1 (es) |
| WO (1) | WO2013068434A1 (es) |
| ZA (1) | ZA201403152B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103333094B (zh) * | 2013-06-19 | 2015-05-13 | 广东肇庆星湖生物科技股份有限公司 | 一种脯氨酸结晶精制的工艺方法 |
| WO2016034602A1 (en) * | 2014-09-05 | 2016-03-10 | F. Hoffmann-La Roche Ag | Solid forms of (2s,4r)-4-[4-(1-methyl-1h-pyrazol-4-yl)-2-trifluoromethyl-benzenesulfonyl]-1-(1-trifluoromethyl-cyclopropanecarbonyl)-pyrrolidine-2-carboxylic acid (1-cyano-cyclopropyl)-amide |
| KR102797060B1 (ko) * | 2016-02-26 | 2025-04-18 | 에프. 호프만-라 로슈 아게 | 신규 피롤리딘 유도체 |
| AR110767A1 (es) * | 2017-01-24 | 2019-05-02 | Astellas Pharma Inc | Compuesto de prolinamida sustituida por fenildifluormetilo |
| AR114732A1 (es) * | 2018-09-18 | 2020-10-07 | Hoffmann La Roche | Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco |
| EP3725769A1 (en) * | 2019-04-17 | 2020-10-21 | Newron Pharmaceuticals S.p.A. | Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives |
| CN111825582B (zh) * | 2020-08-12 | 2022-04-08 | 江西理工大学 | 一种以芳基磺酰氯为硫源合成β-硫代羰基化合物的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4394599A (en) * | 1998-09-09 | 2000-03-27 | Nippon Fine Chemical Co., Ltd. | Process for the preparation of aromatic sulfur compounds |
| CN101475517B (zh) * | 2009-01-15 | 2012-08-15 | 河南大学 | 一种对称的含二硫键化合物的制备方法 |
| EP2421826B1 (en) * | 2009-04-20 | 2013-10-23 | F.Hoffmann-La Roche Ag | Proline derivatives as cathepsin inhibitors |
-
2012
- 2012-11-08 WO PCT/EP2012/072078 patent/WO2013068434A1/en not_active Ceased
- 2012-11-08 SI SI201230621A patent/SI2776392T1/sl unknown
- 2012-11-08 RU RU2014122116A patent/RU2615997C2/ru active
- 2012-11-08 ES ES12783216.0T patent/ES2582643T3/es active Active
- 2012-11-08 US US13/671,586 patent/US8796471B2/en active Active
- 2012-11-08 DK DK12783216.0T patent/DK2776392T3/en active
- 2012-11-08 CN CN201280055223.7A patent/CN103930400B/zh active Active
- 2012-11-08 MY MYPI2014701188A patent/MY167569A/en unknown
- 2012-11-08 EP EP12783216.0A patent/EP2776392B1/en active Active
- 2012-11-08 PL PL12783216.0T patent/PL2776392T3/pl unknown
- 2012-11-08 SG SG11201402030VA patent/SG11201402030VA/en unknown
- 2012-11-08 JP JP2014540444A patent/JP5852254B2/ja active Active
- 2012-11-08 HU HUE12783216A patent/HUE029182T2/en unknown
- 2012-11-08 CA CA2853877A patent/CA2853877C/en active Active
- 2012-11-08 MX MX2014005689A patent/MX339996B/es active IP Right Grant
- 2012-11-08 BR BR112014011248-7A patent/BR112014011248B1/pt not_active IP Right Cessation
- 2012-11-08 KR KR1020147015454A patent/KR101620769B1/ko not_active Expired - Fee Related
- 2012-11-08 AU AU2012334123A patent/AU2012334123B2/en not_active Ceased
- 2012-11-09 AR ARP120104226A patent/AR088816A1/es unknown
-
2014
- 2014-04-30 ZA ZA2014/03152A patent/ZA201403152B/en unknown
- 2014-05-01 IL IL232424A patent/IL232424A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP2776392B1 (en) | 2016-05-18 |
| HK1194733A1 (zh) | 2014-10-24 |
| US8796471B2 (en) | 2014-08-05 |
| US20130123512A1 (en) | 2013-05-16 |
| JP5852254B2 (ja) | 2016-02-03 |
| IL232424A (en) | 2017-01-31 |
| WO2013068434A1 (en) | 2013-05-16 |
| IL232424A0 (en) | 2014-06-30 |
| CN103930400B (zh) | 2016-04-20 |
| KR20140098123A (ko) | 2014-08-07 |
| RU2615997C2 (ru) | 2017-04-12 |
| ES2582643T3 (es) | 2016-09-14 |
| BR112014011248B1 (pt) | 2020-11-17 |
| SI2776392T1 (sl) | 2016-08-31 |
| KR101620769B1 (ko) | 2016-05-12 |
| PL2776392T3 (pl) | 2016-11-30 |
| JP2014532740A (ja) | 2014-12-08 |
| SG11201402030VA (en) | 2014-06-27 |
| ZA201403152B (en) | 2015-07-29 |
| MY167569A (en) | 2018-09-20 |
| HUE029182T2 (en) | 2017-02-28 |
| EP2776392A1 (en) | 2014-09-17 |
| CA2853877A1 (en) | 2013-05-16 |
| DK2776392T3 (en) | 2016-07-04 |
| RU2014122116A (ru) | 2015-12-20 |
| BR112014011248A2 (pt) | 2017-05-09 |
| NZ623851A (en) | 2015-06-26 |
| CN103930400A (zh) | 2014-07-16 |
| CA2853877C (en) | 2019-10-01 |
| AU2012334123B2 (en) | 2016-12-15 |
| MX339996B (es) | 2016-06-21 |
| AU2012334123A1 (en) | 2014-05-01 |
| MX2014005689A (es) | 2014-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
| AR088816A1 (es) | Proceso para preparar derivados de 1-acil-4-fenilsulfonilprolinamida y compuestos intermediarios | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| ES2669189T3 (es) | Compuestos de carbazol útiles como inhibidores del bromodominio | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| CY1120682T1 (el) | Ενωσεις για την προστασια κυτταρων | |
| AR094911A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃ | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| ES2613538T3 (es) | Derivados de arilamida como bloqueadores de TTX-S | |
| AR094342A1 (es) | Derivados de ácido borónico útiles como agentes antimicrobianos | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| UA112993C2 (uk) | Піперазинзаміщені похідні бензотіофену як антипсихотичні агенти | |
| PE20160523A1 (es) | Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis | |
| ES2659222T3 (es) | 7-azabicíclicos sustituidos y su uso para moduladores de receptores de orexina | |
| AR094762A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo | |
| UY31014A1 (es) | Derivados de ftalazinona | |
| EA201171062A1 (ru) | Алкиламидные соединения и их применение | |
| AR083903A1 (es) | Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos | |
| AR088610A1 (es) | Compuestos plaguicidas | |
| CO2018010787A2 (es) | Compuesto de griseofulvina | |
| AR095570A1 (es) | Derivados de urea | |
| AR098965A1 (es) | Derivados de sulfonamidas tricíclicas | |
| ES2568909T3 (es) | Novedosos compuestos antagonistas del receptor de la neuroquinina 1 | |
| AR091499A1 (es) | Derivados de pirimidinonas, su preparacion y su aplicacion en terapeutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |